Idiopathic Short Stature

• FDA approval · 2010-04-12
  FDA Approved: ZOMACTON — Supplemental Application (Ferring Pharmaceuticals Inc.)

  FDA approved a supplemental application for ZOMACTON (somatropin) from Ferring Pharmaceuticals Inc. The action represents an additional regu…

• FDA approval · 2010-02-02
  FDA Approved: GENOTROPIN — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

  FDA approved a supplemental application for Genotropin (somatropin) from Pfizer Laboratories Div Pfizer Inc.

• CLINICAL_TRIALS trial_result · 2009-09-29
  Clinical Trial Update: Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

  This clinical trial update describes a Massachusetts General Hospital study to identify biomarkers of insulin resistance during growth hormo…

• FDA approval · 2007-09-20
  FDA Approved: NORDITROPIN — Supplemental Application (Novo Nordisk)

  FDA approved a supplemental application for Norditropin (somatropin) from Novo Nordisk, indicating an approved update to the existing BLA.

• CLINICAL_TRIALS trial_result · 2007-03-09
  Clinical Trial Update: Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature [Phase 3]

  This update describes an amendment to the unblinded extension phase of a Phase 3 trial of somatropin in idiopathic short stature. The study …

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2006-11-01
  FDA Approved: HUMATROPE — Supplemental Application (Eli Lilly and Company)

  The FDA approved a supplemental application for HUMATROPE (somatropin) submitted by Eli Lilly and Company.

• FDA approval · 2006-10-26
  FDA Approved: HUMATROPE — Supplemental Application (Eli Lilly and Company)

  The FDA approved a supplemental application for HUMATROPE (somatropin) submitted by Eli Lilly and Company.